2-(methylamino)-1-(naphthalen-2-yl)ethanol | 5696-81-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(methylamino)-1-(naphthalen-2-yl)ethanol
• 英文别名: 1-(2-Naphthyl)-2-methylaminoethanol；2-methylamino-1-[2]naphthyl-ethanol；2-Methylamino-1-[2]naphthyl-aethanol；2-Methylamino-1-naphthalen-2-yl-ethanol；2-(methylamino)-1-naphthalen-2-ylethanol
• CAS: 5696-81-1
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: PGJYKUWYKVJKJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(methylamino)-1-(naphthalen-2-yl)ethanol 在 盐酸 、 甲烷磺酸 、 二氯[9,9-二甲基-4,5-二(二苯基膦基)氧杂蒽]钯 、 potassium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 异丙醇 、 乙腈 为溶剂， 反应 33.0h， 生成 (S)-6-(2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine
  参考文献：
  名称：

  [EN] PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES
  [FR] PROCÉDÉS DE PRÉPARATION DE TETRAHYDROISOQUINOLEINES

  摘要：

  公开号：

  WO2014159501A3
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 钯 作用下， 生成 2-(methylamino)-1-(naphthalen-2-yl)ethanol
  参考文献：
  名称：

  β-NAPHTHYL DERIVATIVES OF ETHANOLAMINE AND N-SUBSTITUTED ETHANOLAMINES

  摘要：

  DOI：

  10.1021/jo01211a005

文献信息

• Asymmetric Hydrogenation of α-Primary and Secondary Amino Ketones: Efficient Asymmetric Syntheses of (−)-Arbutamine and (−)-Denopamine
  作者：Gao Shang、Duan Liu、Scott E. Allen、Qin Yang、Xumu Zhang

  DOI：10.1002/chem.200700594

  日期：2007.9.17

  Two beta-receptor agonists (-)-denopamine and (-)-arbutamine were prepared in good yields and enantioselectivities by asymmetric hydrogenation of unprotected amino ketones for the first time by using Rh catalysts bearing electron-donating phosphine ligands. A series of alpha-primary and secondary amino ketones were synthesized and hydrogenated to produce various 1,2-amino alcohols in good yields and

  通过使用带有给电子膦配体的Rh催化剂进行不保护的氨基酮的不对称氢化，以高收率和对映选择性制备了两种β受体激动剂（-）-地巴胺和（-）-arbutamine。合成了一系列的α-伯氨基和仲氨基酮并进行氢化，以高收率和良好的对映选择性生产出各种1,2-氨基醇。这种Rh电子给体的膦催化的不对称氢化反应代表了手性氨基醇不对称合成的最有希望和最方便的方法之一。
• PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES
  申请人：Lobben Paul

  公开号：US20110077400A1

  公开（公告）日：2011-03-31

  Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. Also disclosed are pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression and other conditions and methods for obtaining the crystalline form.

  本发明涉及制备四氢异喹啉的方法，制备四氢异喹啉的中间体，制备这种中间体的方法，以及6-[(4S)-2-甲基-4-(萘基)-1,2,3,4-四氢异喹啉-7-基]吡啶并嗪-3-胺的结晶形式。本发明还涉及包含四氢异喹啉的制药组合物，使用四氢异喹啉治疗抑郁症和其他疾病的方法以及获得结晶形式的方法。
• TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR
  申请人：Bristol-Myers Squibb Company

  公开号：US20130060027A1

  公开（公告）日：2013-03-07

  Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. Also disclosed are pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression and other conditions and methods for obtaining the crystalline form.

  本发明涉及制备四氢异喹啉的方法，用于制备四氢异喹啉的中间体，制备此类中间体的方法，以及6-[(4S)-2-甲基-4-(萘基)-1,2,3,4-四氢异喹啉-7-基]吡啶并嗪-3-胺的结晶形式。还公开了包含四氢异喹啉的药物组合物，使用四氢异喹啉治疗抑郁症和其他疾病的方法以及获得结晶形式的方法。
• Synthesis, in Vitro Activity, and Three-Dimensional Quantitative Structure−Activity Relationship of Novel Hydrazine Inhibitors of Human Vascular Adhesion Protein-1
  作者：Elisa M. Nurminen、Marjo Pihlavisto、László Lázár、Zsolt Szakonyi、Ulla Pentikäinen、Ferenc Fülöp、Olli T. Pentikäinen

  DOI：10.1021/jm100337z

  日期：2010.9.9

  Vascular adhesion protein-1 (VAP-1) belongs to the semicarbazide-sensitive amine oxidases (SSAOs) that convert amines into aldehydes. SSAOs are distinct from the mammalian monoamine oxidases (MAOs), but their substrate specificities are partly overlapping. VAP-1 has been proposed as a target for anti-inflammatory drug therapy because of its role in leukocyte adhesion to endothelium. Here, we describe the synthesis and in vitro activities of novel series of VAP-1 selective inhibitors. In addition, the molecular dynamics simulations performed for VAP-1 reveal that the movements of Met211, Ser496, and especially Leu469 can enlarge the ligand-binding pocket, allowing larger ligands than those seen in the crystal structures to bind. Combining the data from molecular dynamics simulations, docking, and in vitro measurements, the three-dimensional quantitative structure-activity relationship (3D QSAR) models for VAP-1 (q(LOO)(2): 0.636; r(2:) 0.828) and MAOs (q(LOO)(2): 0.749, r(2): 0.840) were built and employed in the development of selective VAP-1 inhibitors.
• US8420811B2
  申请人：——

  公开号：US8420811B2

  公开（公告）日：2013-04-16